GAMIFANT
PeakmAbemapalumab-lzsg
BLAINJECTIONINJECTABLEPriority Review
Approved
Nov 2018
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
4/8 — Partial
Priority Review
GAMIFANT (emapalumab-lzsg) is interferon gamma antagonists [moa]. First approved in 2018.
Drug data last refreshed 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GAMIFANT (emapalumab-lzsg) is a monoclonal antibody that blocks interferon gamma, a key driver of hyperinflammation in hemophagocytic lymphohistiocytosis and related disorders. It is indicated for primary HLH and is being explored off-label across multiple autoimmune, rheumatologic, and lymphoproliferative conditions. The drug targets a novel mechanism distinct from conventional immunosuppression.
$983KPart D
PeakPeak-phase monoclonal antibody with niche indication but significant off-label expansion potential; small commercial team with selective growth opportunities.
Mechanism of Action
Interferon gamma Antagonists
Pharmacologic Class:
Interferon gamma Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
GAMIFANT is a niche-indication biologic with emerging multi-disease potential, creating focused opportunities for specialists in rare disease, immunology, and medical affairs. Peak commercial status with modest Part D spending ($983K) suggests a lean, highly specialized team structure with emphasis on thought leadership and off-label evidence generation.
External Resources
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.